Endothelin 1 (ET-1) was identified as an endothelium-derived, vasoactive 21-amino-acid peptide (34) . The hormone activates two G-protein-coupled receptors, endothelin A (ET A ) and endothelin B (ET B ), with approximately equal affinity (2, 30) . Complex physiology of the endothelin system is suggested by broad tissue distribution of the ligand and its receptors. ET-1 is secreted by many cell types, including endothelial cells and cardiomyocytes (28, 34) , whereas ET A and ET B receptors are expressed by cells such as vascular and nonvascular smooth muscle cells, cardiomyocytes, neurons, and renal tubular epithelial cells (2, 9, 28, 30) . The circulating levels of ET-1 in plasma are 2 orders of magnitude below the concentration needed for receptor activation, suggesting that ET-1 functions locally (4) .
In the heart, ET-1 is produced by cardiomyocytes, fibroblasts, and endothelial cells (9, 28, 34) . The cardiomyocytes predominantly express ET A receptor (9) . The binding of ET-1 to both ET A and ET B receptors on cardiomyocytes results in activation of Gq signaling, increased intracellular calcium, and positive inotropy and chronotropy (5, 17, 19, 27 ; for review, see reference 8). In addition, ET-1 and its receptors mediate stress-induced remodeling in the mammalian heart (for a review, see reference 21) . In vitro experiments show that ET-1-mediated activation of either ET A or ET B receptors on cardiomyocytes results in cellular hypertrophy (7, 18) . In vivo studies demonstrate that levels of ET-1 and ET A are elevated in animal models of congestive heart failure (29, 35, 36) . Providing the final proof of endothelins' molecular role in cardiac pathology, endothelin receptor antagonists inhibit the progression of cardiac remodeling in animal models of congestive heart failure (25, 28, 33) .
Even though pharmacological effects of endothelins are well-known, detailed tissue-specific roles of ET-1 and its receptors have never been outlined in vivo. This is in part because of neonatal lethality of systemic ET A and ET-1 knockout mice due to developmental defects in cardiac and craniofacial structures (6, 23) . Therefore, utilizing the cre/loxP technology (13), we have generated mice in which the ET A gene can be deleted in a selected cell population (20) . In the present study, we deleted the ET A gene in cardiomyocytes by crossing mice with loxP-flanked ET A (ET A flox ) alleles with transgenic mice that express cre recombinase under the control of the cardiomyocyte-specific ␣-myosin heavy-chain promoter (1) . The mice with cardiomyocyte-specific deletion of ET A are viable and were used to study the role of ET A in cardiac physiology and stress response to angiotensin II or isoproterenol.
MATERIALS AND METHODS
Generation of cardiomyocyte-specific ET A knockout mice. The conditional ET A knockout construct ( Fig. 1 ) was used to generate homozygous ET A flox/flox mice as previously described (20) . To target deletion of the ET A gene to cardiomyocytes, the mice were bred with animals that express cre recombinase from the transgene driven by the ␣-myosin heavy chain (␣-MHC) promoter [cre(Tg)] (1). The specificity and efficiency of cre-mediated recombination in cardiomyocytes was evaluated by crossing cre(Tg) mice with CAG-CAT-lacZ transgenic mice, a line that expresses functional ␤-galactosidase only after cre-mediated recombination (3). The hearts from cre(Tg); CAG-CAT-lacZ(Tg) and cre(Ϫ); CAG-CAT-lacZ(Tg) males were harvested, whole-mount ␤-galactosidase stained, and sectioned as previously described (22) . The genetic background of the mice used in the present study was a mixture of C57BL/6J, 129/S6, and FVB/N strains (1) (1) . Detection of cre recombinase-induced ET A flox deletion. DNA was isolated from hearts, lungs, livers, and brains of 2-month-old male mice. Approximately 20 g of DNA was digested with BamHI, separated on an agarose gel, acid fragmented, transferred to a nylon membrane (Hybond N ϩϩ ), and subjected to Southern blot analysis with a 5Ј-internal probe (Fig. 1) . The ET A wt allele, ET A flox allele, and cre recombinase-deleted ET A flox allele yielded 24-, 12-, and 3.8-kb fragments, respectively ( Fig. 1) .
Real-time RT-PCR. Total RNA was isolated from hearts of 6-week-old male mice by using Trizol (Gibco-BRL) according to the manufacturer's protocols. Reverse transcription (RT) was carried out by using oligo(dT) primer and the Superscript choice system (Gibco-BRL). Real-time PCR was performed by using SYBR Green PCR Master Mix with a 400 nM concentration of each primer in a model 5700 Thermocycler (Applied Biosystems). The primers used for quantitation were as follows: 5Ј-CTGAAAACAATTTTTGAATTTCTTGC-3Ј and 5Ј-TACCAAGATGTGAAGGACTGGTGG-3Ј for ET A mRNA, 5Ј-GTAACAT GCAATCGCCCGCA-3Ј and 5Ј-GGAACCCCAATTCCTTTAA-3Ј for ET B mRNA, 5Ј-ACAGTCCGCCTAGAAGCACT-3Ј and 5Ј-TCCGATGCCCTGAG GCTCTT-3Ј for ␤-actin mRNA; and 5Ј-TGCACCACCAACTGCTTAG-3Ј and 5Ј-GGATGCAGGGATGATGTTC-3Ј for GAPDH mRNA. The PCR was run for 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 94°C, 20 s at 55°C, and 30 s at 72°C. PCR products were present only in reverse transcriptase-primed samples: 390 bp for ET A mRNA, 250 bp for ET B mRNA, 390 bp for ␤-actin mRNA, and 175 bp for GAPDH mRNA.
Radioligand-binding assay. The binding assay was performed as previously described (30) by using 90 mg of cardiac protein preparation and 125 I-labeled ET-1 (2,000 Ci/mmol; Amersham). The protein extracts were obtained from hearts of 6-week-old males by homogenization in 3 ml of extraction buffer (25 mM Tris-HCl [pH 7.5], 135 mM NaCl, 27 mM KCl, 1. . Mouse echocardiography and necropsy. Echocardiography was conducted before osmotic pump implantation and repeated 10 days after the procedure. For echocardiography, the mice were anesthetized (35 mg of ketamine and xylazine each/kg) and subjected to measurements with S12 probe and SONOS 5500 (Philips Medical Imaging, Andover, Mass.) as previously described (32) . Twodimensional echocardiography in a mid-ventricular short-axis view was used to guide measurements of left ventricular (LV) end-diastolic and end-systolic dimensions, fractional shortening, and wall thickness. Apical long-axis view was used to guide Doppler measurements of LV outflow tract velocity, ejection time, and aortic velocity time integral. To determine weight of hearts, lungs, livers, and kidneys, the organs were collected from 6-week-old male mice sacrificed by using carbon dioxide. Eight animals from each genotype were used for the analysis. To examine cardiac anatomy and histology, hearts were frozen in OCT, sectioned at the plane of aortic valve to the cardiac apex, and stained with hematoxylin and eosin. The representative images are slides scanned by using Optronics chargecoupled device camera.
Statistics. Experimental data are expressed as the mean value Ϯ the standard error of the mean. Group data are analyzed by analysis of variance. Differences among groups are considered statistically significant for P Ͻ 0.05.
RESULTS

Generation of cardiomyocyte-specific ET A knockout mice.
Generation of the homozygous loxP-flanked ET A (ET A flox/flox ) mice has been previously described (20) . These mice grow normally into adulthood without any health problems. In order to delete the ET A gene specifically in cardiomyocytes, the ET A flox/flox mice were bred with transgenic animals which express cre recombinase under the control of cardiomyocyte- Southern blot analysis of genomic DNA digested with BamHI and hybridized with the 5Ј probe (Fig. 1) produced the expected 24-and 12-kb bands in the ET A wt/wt mice and the ET A flox/flox mice, respectively (Fig. 2b) . In addition, the 3.8-kb band (Fig. 2b) (Fig. 2b) .
Real-time RT-PCR showed a statistically significant reduction (78%) in the ET A mRNA level and no change in the ET B mRNA level in the hearts of cre(Tg); ET A flox/flox mice compared to the genetic controls (Fig. 3a) . Similar results were obtained when either ␤-actin mRNA or GAPDH mRNA (results not shown) was used as an internal standard.
Due to lack of available antibodies specific to ET A receptor that can be used for immunohistochemistry, we instead used radioligand-binding assay for this purpose. The mice and their genetic controls were sacrificed at 6 weeks of age to document cardiac anatomy and weight. The hearts of cardiomyocyte-specific ET A knockout mice had normal anatomy and histology of the right ventricular and LV wall and interventricular septum (Fig. 4) . The cardiac weight was 0.60% Ϯ 0.02% of body weight, a finding similar to the cardiac weight of controls: 0.63% Ϯ 0.01% for the cre(Ϫ); ET A wt/wt mice, 0.63% Ϯ 0.02% for the cre(Tg); ET A wt/wt mice, and 0.64% Ϯ 0.02% for the cre(Ϫ); ET A flox/flox mice (Table 1) . To document inotropy and chronotropy, anesthetized 10-week-old male mice were subjected to echocardiography. The LV internal dimensions, wall thickness, fractional shortening, and LV mass of cre(Tg); ET A flox/flox animals did not differ from the genetic controls (data not shown). In addition, cardiomyocyte-specific ET A knockout animals' peak velocity of left outflow tract (Vp; 71.2 Ϯ 3.5 cm/s), aortic velocity time integral (3.60 Ϯ 0.15 cm), ejection time (76 Ϯ 3 ms), and heart rate (337 Ϯ 15 bpm) did not differ from the genetic controls ( (32) , with the exception of aortic velocity time integral, which, to our knowledge, has not been previously reported.
The cardiomyocyte-specific ET A knockout mice exhibit similar hypertrophic response to infusion of angiotensin II or isoproterenol as the control animals. Since cre(Tg); ET A flox/flox mice have normal cardiac anatomy and basal contractility, we extended our studies to find possible differences among the genotypes in response to cardiac stress induced by continuous infusion of angiotensin II or isoproterenol. The cardiomyocyte-specific ET A knockout male mice and their genetic controls were subjected to baseline echocardiography and then were infused via osmotic pump for 10 days with either saline, angiotensin II, or isoproterenol. The animals were again examined by echocardiography after the infusion period. Continuous infusion of saline resulted in no changes in Vp and ejection time in the cre(Tg); ET A flox/flox mice and the genetic controls (Table 2 ). Compared to the saline treatment, infusion of angiotensin II led to similar increases (ca. 8%) of the heart weight of all genotypes ( Table 2 ). Angiotensin II treatment did not change peak velocity and ejection time in either the cardiomyocyte-specific ET A knockout mice or the genetic controls. Compared to the saline treatment, infusion of isoproterenol led to similar increases (ca. 30%) in the heart weight in all genotypes (Table 2 ). Compared to the baseline measurements, isoproterenol treatment increased peak velocity and decreased ejection time equally in the cardiomyocyte-specific ET A knockout animals and the genetic controls. Similar degrees of cardiac hypertrophy have been reported in response to angiotensin II or isoproterenol infusion in wild-type mice (10).
DISCUSSION
ET-1 acts as a local factor involved in cardiac and craniofacial development, as well as in the regulation of cardiac contractility and hypertrophy (21) . However, our knowledge of endothelin physiology is still fragmentary due to several factors, including broad expression of ET-1 and its receptors and neonatal lethality of both systemic ET-1 and ET A knockouts (6, 23) . In order to broaden our current knowledge of endothelin biology, we generated mice with loxP-flanked ET A allele. In these mice, the ET A gene can be deleted in a selected cell population by cell-specific expression of cre recombinase transgene. We have already successfully deleted the ET A gene selectively in smooth muscle cells by using cre recombinase driven by smooth muscle MHC promoter (20) . The deletion of ET A from smooth muscle cells has resulted in hypotensive phenotype in these mice.
The goal of current study was to define the cardiac role of ET A receptors. By using mice expressing cre recombinase under the control of ␣-MHC promoter, we targeted ET A gene deletion to cardiomyocytes. The success of ET A gene deletion was confirmed by Southern blot analysis, real-time RT-PCR, and ET-1 radioligand-binding assay. Southern blot analysis showed the presence of deleted ET A allele in the heart but not in other organs of cre(Tg); ET A flox/flox mice. The similar intensities of deleted and nondeleted ET A alleles in Fig. 2b The cardiomyocyte-specific ET A knockout mice are viable and have no detectable abnormalities in cardiac anatomy and weight. The ET A knockout mice also have similar cardiac contractility (as measured by Vp), aortic velocity time integral, ejection time, and heart rate) as the genetic controls. Although ET-1 has been reported to have a positive inotropic and chronotropic effect via the ET A receptor (5, 17, 19, 27) , our results suggest that ET A receptor on murine cardiomyocytes is dispensable for the maintenance of basal cardiac anatomy, inotropy, and chronotropy.
The cardiomyocyte-specific ET A knockout mice also exhibited similar hypertrophic response to 10-day infusion of angiotensin II or isoproterenol compared to the control animals. This is a surprising result since multiple studies suggested a role of ET A receptor in these pharmacologically induced hypertrophies. First, angiotensin II and isoproterenol have been shown to increase levels of ET-1 in cultured rat cardiomyocytes (18, 24) . Second, ET A receptor antagonists reduced angiotensin II-mediated cardiomyocyte hypertrophy in vitro (18) . Third, the combined ET A /ET B receptor antagonist bosentan inhibited angiotensin II-induced cardiac hypertrophy and arterial hypertension in rats (16) . In contrast to these results, our findings demonstrate that angiotensin II-and isoproterenolinduced hypertrophies do not require the presence of ET A receptors on cardiomyocytes. However, since we found that the protein levels of ET B receptor is twofold higher in the hearts of ET A knockout mice compared to the genetic controls, ET B may be compensating for the lack of ET A receptors on cardiomyocytes. Another possibility is that ET-1 produced within the heart acts primarily on the ET A receptors on cardiac fibroblasts in order to induce cardiac remodeling. In several studies, endothelin signaling through cardiac fibroblasts has been shown to play an active role in the induction of cardiac remodeling (9, 11; for review, see reference 26). Furthermore, the observed elevated levels of ET B receptors in the hearts of ET A knockout mice also demonstrate the presence of complex mechanisms that control levels of ET A and ET B receptors in cardiac tissue. Similar results, i.e., the lack of protection from pressureinduced myocardial hypertrophy, were reported in mice lacking angiotensin II receptor type 1A (AT 1A ) (14, 15) . This was unexpected since pharmacological antagonism of AT 1 angiotensin receptor is widely used in prevention of cardiac remodeling in both animal models and patients (for review, see reference 12). Thus, both the cardiomyocyte-specific knockout of ET A receptor and the systemic knockout of AT 1A angiotensin II receptor do not recapitulate the pharmacological benefits of ET A and AT 1 antagonism in cardiac hypertrophy (25, 28, 33) . These discrepancies await further studies.
